Equities

Zhongzhi Pharmaceutical Holdings Ltd

Zhongzhi Pharmaceutical Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.95
  • Today's Change0.05 / 5.56%
  • Shares traded54.00k
  • 1 Year change-28.57%
  • Beta0.4186
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Zhongzhi Pharmaceutical Holdings Ltd is a China-based investment holding company. The Company is principally engaged in the research and development, manufacturing and sales of Chinese patent medicines and decoction pieces (consisting of traditional decoction pieces and modern decoction pieces). The Company operates through three segments: pharmaceutical manufacturing segment, operation of chain pharmacies in Zhongshan, Guangdong Province and operation of on-line pharmacies. The Company’s brands include Zeus, Liumian and Caojinghua. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)2.25bn
  • Net income in HKD122.77m
  • Incorporated2014
  • Employees2.74k
  • Location
    Zhongzhi Pharmaceutical Holdings LtdNo.3 Kangtai Road SouthTorch Development ZoneZHONGSHAN ChinaCHN
  • Phone+86 76 085331222
  • Fax+86 76 085318764
  • Websitehttp://www.zeus.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Transcenta Holding Ltd24.63m-395.54m452.80m200.00--0.4229--18.39-0.974-0.9740.06072.460.01310.81060.5768114,540.40-21.08---29.77--26.02---1,606.19--1.04-31.650.2826---47.15---13.72------
Uni-Bio Science Group Ltd508.40m98.86m474.60m458.004.851.503.990.93350.01590.01590.08120.05141.272.239.051,249,140.0024.761.4632.971.9783.5180.5919.441.232.17168.550.22670.0010.0829.0884.04--84.98--
Tianda Pharmaceuticals Ltd384.68m-47.26m509.56m695.00--0.9358--1.32-0.022-0.0220.17890.25330.43412.974.46445,745.10-5.34---7.97--45.83---12.30--0.6748-9.510.1536--------------
3D Medicines Inc539.11m-495.99m557.73m198.00--0.5964--1.03-2.11-2.112.263.620.37464.945.792,722,764.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Lee's Pharmaceutical Holdings Ltd1.20bn63.06m694.83m1.06k11.020.40553.540.57950.10710.10712.042.910.44032.119.701,134,410.001.9813.332.5217.7651.4961.924.5036.200.74256.120.1323.59-14.61-1.53-67.44-47.49-12.19-31.34
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd925.32m189.30m733.93m678.003.880.41995.780.79320.33790.33791.653.120.35742.102.941,091,177.007.317.6710.2510.4875.4678.7920.4620.681.62--0.05027.22-0.00495.38-23.43-1.67-1.14--
Zhaoke Ophthalmology Ltd63.10m-250.42m748.21m297.00--0.3337--11.86-0.4597-0.45970.11584.110.02331.250.8868201,601.40-9.23---10.51--82.03---396.86--5.48-24.020.1114------5.47------
Fusen Pharmaceutical Co Ltd469.27m-98.90m749.96m1.14k--1.31--1.60-0.1326-0.13260.62990.76540.32121.683.35408,769.60-6.770.9678-13.961.7453.1851.95-21.082.590.526-2.270.403127.9515.024.13-4.83--0.2124--
Jbm (Healthcare) Ltd648.42m130.46m756.24m279.006.220.78794.121.170.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
Pak Fah Yeow International Ltd265.21m96.45m804.03m101.008.341.077.753.030.30940.30940.85072.410.28692.8423.532,600,118.0010.443.9911.324.1887.0580.7936.3721.274.225.260.0055100.6876.0612.94250.6623.0218.83-8.06
Zhongzhi Pharmaceutical Holdings Ltd2.25bn122.77m820.42m2.74k6.550.67223.900.3640.1450.1452.661.411.092.686.10852,889.205.997.699.1711.7557.5560.445.496.730.903343.870.151642.4612.2612.4153.0013.8617.653.22
Hbm Holdings Ltd562.82m166.02m952.48m158.005.500.95124.851.690.22570.22570.76341.300.32583.9616.673,179,801.009.59-54.6113.25-66.0495.5797.8129.42-400.283.448.140.3502--120.13127.06116.61---12.62--
Ascletis Pharma Inc11.13m-285.07m997.39m219.00--0.4212--89.63-0.2746-0.27460.01072.370.00411.343.5850,813.03-10.47-6.43-10.85-6.64-125.1735.67-2,561.69-243.3824.31-4.180.004--4.63-19.3954.04---20.44--
Jacobson Pharma Corporation Ltd1.47bn210.24m1.18bn1.72k5.390.49253.350.8040.10950.13910.76441.200.33112.476.37851,885.104.744.305.765.5742.2741.2514.3213.731.735.330.238240.6215.79-0.14011.31-3.0524.064.10
Data as of Sep 20 2024. Currency figures normalised to Zhongzhi Pharmaceutical Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Lazard Asset Management LLCas of 31 Aug 202469.00k0.01%
FIL Investments Internationalas of 30 Jun 202363.00k0.01%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.